GLP-1RA Discontinuation Leads to Significant Weight Regain; Tirzepatide Shows Higher Rebound Than Semaglutide
Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysis.
Abstract
Discontinuing GLP-1RAs causes significant weight regain (MD = 17.90%), with tirzepatide showing higher rebound than semaglutide.
